Celsion

Celsion completes acquisition of Egen

Friday, June 20, 2014

Celsion, an oncology drug development company, has completed its acquisition of substantially all of the assets of Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes Egen’s phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

[Read More]

Celsion to acquire Egen

Wednesday, June 11, 2014

Celsion, an oncology drug development company, and Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, have signed a definitive asset purchase agreement for Celsion to acquire substantially all of Egen’s assets, including its phase Ib DNA-based immunotherapy product candidate Egen-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

[Read More]

Celsion reappoints Jeffrey W. Church CFO

Tuesday, July 9, 2013

Biopharmaceutical Celsion has announced Jeffrey W. Church, senior vice president, will resume the role of chief financial officer, a position he held prior to his promotion to senior vice president in July 2011.  In this position he will retain responsibility for corporate investor relations.

[Read More]